1JNJ Stock Chart & Stats
€235.60
€4.50(1.95%)
At close: 4:00 PM EDT
€235.60
€4.50(1.95%)
Day’s Range― - ―
52-Week Range€133.00 - €241.55
Previous CloseN/A
Volume145.00
Average Volume (3M)266.00
Market Cap
€535.68B
Enterprise Value€649.67K
Total Cash (Recent Filing)€20.76B
Total Debt (Recent Filing)€49.04B
Price to Earnings (P/E)29.6
Beta0.17
Next Earnings
Oct 20, 2026EPS Estimate
2.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.65
Shares Outstanding2,409,898,700
10 Day Avg. Volume238
30 Day Avg. Volume266
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)6.18
Price to Sales (P/S)5.35
P/FCF Ratio25.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€244.07Price Target Upside3.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)10.09
Revenue Forecast (FY)€87.96B
Bulls Say, Bears Say
Bulls Say
High Profitability And Margin SustainabilityJohnson & Johnson’s trailing‑12‑month gross, operating and net margins are very strong, reflecting durable pricing power, efficient cost structure, and scale across pharmaceuticals and MedTech. High core margins support sustained R&D investment, product launches, and long‑term cash returns to stakeholders.
Robust Cash Generation And Conservative LeverageConsistent free cash flow conversion and low relative debt create meaningful financial flexibility. A large cash balance plus modest leverage supports M&A, pipeline funding, and shareholder programs without relying on high recurring borrowing, reducing financial risk over the medium term.
Diversified High‑Growth Product Mix And Pipeline/M&ABroadly diversified growth across multiple recent launches and established brands reduces single‑product dependence. Active pipeline catalysts plus targeted M&A (e.g., Firefly) enhance oncology and novel modality capabilities, improving medium‑term revenue resilience and strategic positioning.
Bears Say
STELARA Biosimilar Impact And Legacy Product DeclineA >50% decline in a legacy biologic demonstrates how biosimilar entry and therapeutic class shifts can rapidly erode material revenue streams. Replacing that cash flow requires successful new launches and sustained uptake, creating revenue volatility over multiple quarters.
MedTech Procedure Sensitivity And Regional Inventory PressureMedTech revenue is exposed to procedure volumes, physician preference and regional inventory cycles. Slower cardiology demand, selectivity after neutral trials, and China inventory distortions can depress growth for an extended period until procedure volumes, trial readouts and inventory normalization occur.
Legal/Liability And Near‑Term Earnings Dilution From DealsLarge contingent litigation exposure and recent M&A accounting charges create near‑term cash and EPS pressure. Settlement obligations and in‑process R&D write‑offs reduce free cash available for strategic uses and introduce execution and timing risk for returning normalized earnings power.
Johnson & Johnson News
1JNJ FAQ
What was Johnson & Johnson’s price range in the past 12 months?
Johnson & Johnson lowest stock price was €133.00 and its highest was €241.55 in the past 12 months.
What is Johnson & Johnson’s market cap?
Johnson & Johnson’s market cap is €535.68B.
When is Johnson & Johnson’s upcoming earnings report date?
Johnson & Johnson’s upcoming earnings report date is Oct 20, 2026 which is in 76 days.
How were Johnson & Johnson’s earnings last quarter?
Johnson & Johnson released its earnings results on Jul 15, 2026. The company reported €2.519 earnings per share for the quarter, beating the consensus estimate of €2.48 by €0.039.
Is Johnson & Johnson overvalued?
According to Wall Street analysts Johnson & Johnson’s price is currently Undervalued.
Does Johnson & Johnson pay dividends?
Johnson & Johnson does not currently pay dividends.
What is Johnson & Johnson’s EPS estimate?
Johnson & Johnson’s EPS estimate is 2.56.
How many shares outstanding does Johnson & Johnson have?
Johnson & Johnson has 2,409,898,700 shares outstanding.
What happened to Johnson & Johnson’s price movement after its last earnings report?
Johnson & Johnson reported an EPS of €2.519 in its last earnings report, beating expectations of €2.48. Following the earnings report the stock price went down -0.226%.
Which hedge fund is a major shareholder of Johnson & Johnson?
Currently, no hedge funds are holding shares in IT:1JNJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Johnson & Johnson Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€244.07 (3.60% Upside)
€244.07 (3.60% Upside)
Blogger Sentiment
Bullish
IT:1JNJ Sentiment 86%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth €7.2M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
58.31%
12-Months-Change
Fundamentals
Return on Equity
2.01%
Trailing 12-Months
Asset Growth
3.97%
Trailing 12-Months
Company Description
Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
1JNJ Company Deck
1JNJ Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was broadly positive: the company reported solid top‑line growth, strong performance from a broad set of Innovative Medicine launches (many products delivering high double‑digit growth), successful new product launches (ICOTYDE, INLEXZO), raised guidance for full‑year sales and EPS, and improved operating margin expectations. Headwinds exist — notably STELARA's steep decline, MedTech pressure in cardiovascular/Abiomed, regional inventory impacts (China), higher other expenses and a higher GAAP tax rate — but management characterized these as addressable and emphasized diversified, multi‑product strength, cash flow recovery, and upcoming pipeline and regulatory catalysts.View all IT:1JNJ earnings summaries1JNJ Sales Breakdown
64.12% Innovative Medicine
35.88% MedTech
1JNJ Stock 12 Month Forecast
Average Price Target
€244.07
▲(3.60% Upside)